Portage Biotech (NASDAQ:ALP – Get Free Report) and VeriSign (NASDAQ:VRSN – Get Free Report) are both technology companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership and dividends.
Institutional & Insider Ownership
13.4% of Portage Biotech shares are owned by institutional investors. Comparatively, 92.9% of VeriSign shares are owned by institutional investors. 0.6% of VeriSign shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares Portage Biotech and VeriSign’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Portage Biotech | N/A | N/A | N/A |
| VeriSign | 49.06% | -38.40% | 59.95% |
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Portage Biotech and VeriSign, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Portage Biotech | 1 | 2 | 0 | 0 | 1.67 |
| VeriSign | 0 | 2 | 4 | 0 | 2.67 |
Portage Biotech currently has a consensus price target of $12.50, suggesting a potential upside of 495.24%. VeriSign has a consensus price target of $352.00, suggesting a potential upside of 14.71%. Given Portage Biotech’s higher probable upside, equities research analysts plainly believe Portage Biotech is more favorable than VeriSign.
Earnings and Valuation
This table compares Portage Biotech and VeriSign”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Portage Biotech | $100,000.00 | 32.55 | -$38.63 million | ($409.00) | -0.01 |
| VeriSign | $1.66 billion | 16.62 | $825.70 million | $9.30 | 33.00 |
VeriSign has higher revenue and earnings than Portage Biotech. Portage Biotech is trading at a lower price-to-earnings ratio than VeriSign, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Portage Biotech has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500. Comparatively, VeriSign has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500.
Summary
VeriSign beats Portage Biotech on 10 of the 13 factors compared between the two stocks.
About Portage Biotech
Portage Biotech was a clinical-stage biotechnology company focused on developing immuno-oncology treatments for cancer. Its research centered on therapies intended to help the immune system recognize and attack tumors. The company’s pipeline included programs targeting invariant natural killer T cells and other immune pathways, including mechanisms within the tumor microenvironment. Its work was aimed at developing treatments that could be used alone or alongside other cancer therapies. Portage Biotech operated as a development-stage company, with its programs primarily in research and clinical development rather than commercial sales.
About VeriSign
VeriSign, Inc. operates critical internet infrastructure, best known for managing the domain-name registries for .com and .net. It provides the systems that allow domain names in these extensions to be registered and resolved through the Domain Name System, working with registrars that serve businesses and individuals. The company also provides registry services for other domain extensions and supports the security and stability of the internet’s naming infrastructure. Its services are used globally through a network of registrars and other internet service providers.
Receive News & Ratings for Portage Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portage Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
